SAT-057 Patient and Caregiver Preferences for Once-Weekly Injection Devices for the Treatment of Growth Hormone Deficiency

Abstract Disclosure: J. Chen: Novo Nordisk. B.S. Miller: Abbvie, Amgen Inc, Ascendis Pharma, BioMarin, Endo Pharmaceuticals, Eton Pharmaceuticals, Novo Nordisk, Pfizer, Inc., Sanofi, Soleno, Tolmar, Alexion Pharmaceuticals, Inc., Aeterna Zentaris, Foresee, Lumos Pharma, OPKO Health, Sangamo Therapeutics. N. Kelepouris: Novo Nordisk. B. Kantor: Novo Nordisk. L. Marin: Novo Nordisk. C. Platt: Novo Nordisk. K.C. Yuen: Crinetics, Ascendis Pharma, Chiesi, Novo Nordisk, Ipsen, Recordati. Background: Untreated growth hormone deficiency (GHD) results in short stature in children and other metabolic-related health complications in adults. Once-weekly long-acting growth hormone analog (LA-GHA) injection devices offer a more viable treatment option for patients with GHD, which previously consisted of once-daily injections. We aimed to understand injection/device attributes that are important to patients and caregivers (CGs) when considering LA-GHA options. Methods: Adults (aged ≥18 years), CGs of children (aged 3-11 years), and adolescents (aged 12-17 years) with GHD completed an online survey, including a discrete choice experiment (DCE). The DCE comprised a series of choice tasks in which respondents chose between hypothetical, experimentally designed, once-weekly LA-GHA treatment devices. Each choice task included attributes related to the device (type, shape/size), convenience (dose loading, preparation time, number of injections for 1 full dose, storage), and safety (post-injection pain), each with varying levels. Attributes and levels were developed from a targeted literature review, qualitative interviews with patients and CGs, and clinical expert input. Included individuals were those residing in the United States, reporting a GHD diagnosis for themselves or a patient aged 3-17 years for whom they provided care, and who were currently taking short-acting GH injections. A hierarchical Bayesian model estimated part-worth utilities for each DCE attribute level, which were used to calculate the relative importance of each attribute (ranging from 0% to 100%). Preference share was estimated to calculate the probability that a respondent would prefer each device profile relative to others in each scenario. Results: One hundred patients with GHD/CGs participated: n=50 adults and n=25 CGs of children self-administered the survey; n=25 adolescents completed the online survey during a moderator-assisted interview with their CG present. The relative importance of attributes driving device preference did not vary by cohort; the most important LA-GHA attributes identified in the survey were post-injection pain (27%), followed by the number of injections needed for 1 full dose (23%) and time needed to prepare the device before each injection (16%). Respondents reported a strong preference (82%) for the device profile with attribute levels resembling somapacitan-beco over other LA-GHA device profiles, which was similar for each cohort (81%-85%). Respondents preferred LA-GHA devices with low rates of injection pain, 1 injection per dose, short preparation time, small device size, and long room-temperature stability. Conclusion: Factors such as injection pain and convenience have the greatest impact on patient preferences for LA-GHA devices. Less pain and superior convenience may lead to better patient adherence and clinical outcomes in treating GHD. Presentation: Saturday, July 12, 2025